The Impact of COVID-19 Lockdown on Adults with Major Depressive Disorder from Catalonia: A Decentralized Longitudinal Study.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
15 03 2023
Historique:
received: 27 01 2023
revised: 03 03 2023
accepted: 07 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

The present study analyzes the effects of each containment phase of the first COVID-19 wave on depression levels in a cohort of 121 adults with a history of major depressive disorder (MDD) from Catalonia recruited from 1 November 2019, to 16 October 2020. This analysis is part of the Remote Assessment of Disease and Relapse-MDD (RADAR-MDD) study. Depression was evaluated with the Patient Health Questionnaire-8 (PHQ-8), and anxiety was evaluated with the Generalized Anxiety Disorder-7 (GAD-7). Depression's levels were explored across the phases (pre-lockdown, lockdown, and four post-lockdown phases) according to the restrictions of Spanish/Catalan governments. Then, a mixed model was fitted to estimate how depression varied over the phases. A significant rise in depression severity was found during the lockdown and phase 0 (early post-lockdown), compared with the pre-lockdown. Those with low pre-lockdown depression experienced an increase in depression severity during the "new normality", while those with high pre-lockdown depression decreased compared with the pre-lockdown. These findings suggest that COVID-19 restrictions affected the depression level depending on their pre-lockdown depression severity. Individuals with low levels of depression are more reactive to external stimuli than those with more severe depression, so the lockdown may have worse detrimental effects on them.

Identifiants

pubmed: 36982069
pii: ijerph20065161
doi: 10.3390/ijerph20065161
pmc: PMC10048808
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Front Psychol. 2020 Nov 17;11:586246
pubmed: 33281685
Psychol Med. 2021 Apr;51(6):1054-1056
pubmed: 32423496
IEEE Trans Biomed Eng. 2021 Apr;68(4):1273-1281
pubmed: 32960759
Global Health. 2021 Mar 29;17(1):34
pubmed: 33781283
Psychiatry Res. 2020 Sep;291:113190
pubmed: 32563745
Schizophr Res. 2020 Sep;223:192-198
pubmed: 32771308
Lancet Psychiatry. 2021 Feb;8(2):121-129
pubmed: 33306975
J Affect Disord. 2021 Feb 15;281:13-23
pubmed: 33279864
Psychiatry Res. 2020 Oct;292:113345
pubmed: 32745794
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
Psychiatr Q. 2021 Jun;92(2):683-691
pubmed: 32889688
BMJ. 2020 Jan 28;368:m313
pubmed: 31992552
Psychiatry Res. 2020 Sep;291:113265
pubmed: 32763536
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Front Psychiatry. 2020 Oct 30;11:576935
pubmed: 33329114
Int J Environ Res Public Health. 2021 Mar 21;18(6):
pubmed: 33801095
World J Psychiatry. 2021 Dec 19;11(12):1387-1406
pubmed: 35070784
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Psychiatry Res. 2020 Oct;292:113317
pubmed: 32721785
Global Health. 2020 Jul 6;16(1):57
pubmed: 32631403
BMC Psychiatry. 2019 Feb 18;19(1):72
pubmed: 30777041
J Affect Disord. 2021 Dec 1;295:1335-1346
pubmed: 34706447
Psychiatr Q. 2020 Dec;91(4):1033-1045
pubmed: 32642822
Behav Med. 2017 Oct-Dec;43(4):307-322
pubmed: 27100966
Int J Environ Res Public Health. 2021 Jun 17;18(12):
pubmed: 34204403
Int J Environ Res Public Health. 2021 Jul 01;18(13):
pubmed: 34281004
EClinicalMedicine. 2021 Apr;34:100806
pubmed: 33842872
Am J Geriatr Psychiatry. 2020 Sep;28(9):924-932
pubmed: 32682619
J Clin Med. 2022 Dec 01;11(23):
pubmed: 36498739
Psychol Med. 2021 Apr;51(6):881-893
pubmed: 33648613
Brain Behav Immun. 2020 Jul;87:99
pubmed: 32360604
JMIR Mhealth Uhealth. 2019 Aug 01;7(8):e11734
pubmed: 31373275
J Anxiety Disord. 2020 Aug;74:102271
pubmed: 32673930
J Affect Disord. 2022 Jan 1;296:567-576
pubmed: 34600966
J Affect Disord. 2022 Aug 1;310:106-115
pubmed: 35525507
Lancet Public Health. 2022 May;7(5):e417-e426
pubmed: 35461592
Brain Behav Immun. 2020 Jul;87:100-106
pubmed: 32353518
BMC Psychiatry. 2021 Sep 6;21(1):435
pubmed: 34488697
Compr Psychiatry. 2022 Jan 31;114:152298
pubmed: 35123177
J Glob Health. 2020 Dec;10(2):020505
pubmed: 33110588
J Med Internet Res. 2020 Sep 25;22(9):e19992
pubmed: 32877352

Auteurs

Raffaele Lavalle (R)

Dipartimento di Neuroscienze, Università degli Studi di Torino, 10124 Turin, Italy.

Elena Condominas (E)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Josep Maria Haro (JM)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Iago Giné-Vázquez (I)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Raquel Bailon (R)

Aragón Institute of Engineering Research (I3A), Instituto de Investigación Sanitaria de Aragón (IIS Aragón), University of Zaragoza, 50018 Zaragoza, Spain.
Centros de Investigación Biomédica en Red en el área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.

Estela Laporta (E)

Centros de Investigación Biomédica en Red en el área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.

Ester Garcia (E)

Centros de Investigación Biomédica en Red en el área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.
Microelectrónica y Sistemas Electrónicos, Universidad Autónoma de Barcelona, 08193 Bellaterra, Spain.

Spyridon Kontaxis (S)

Aragón Institute of Engineering Research (I3A), Instituto de Investigación Sanitaria de Aragón (IIS Aragón), University of Zaragoza, 50018 Zaragoza, Spain.
Centros de Investigación Biomédica en Red en el área de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid, Spain.

Gemma Riquelme Alacid (GR)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Federica Lombardini (F)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Antonio Preti (A)

Dipartimento di Neuroscienze, Università degli Studi di Torino, 10124 Turin, Italy.

Maria Teresa Peñarrubia-Maria (MT)

Health Technology Assessment in Primary Care and Mental Health (PRISMA) Research Group, Parc Sanitari Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, 08830 St Boi de Llobregat, Spain.
Unitat de Suport a la Recerca Regió Metropolitana Sud, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), 08007 Barcelona, Spain.

Marta Coromina (M)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Belén Arranz (B)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Elisabet Vilella (E)

Hospital Universitari Institut Pere Mata, 43206 Reus, Spain.
Neuriociències i Salut Mental, Institut d'Investigació Sanitària Pere Virgili-CERCA, 43204 Reus, Spain.
Universitat Rovira i Virgili, 43003 Reus, Spain.
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Elena Rubio-Alacid (E)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.
Centro de Investigación Biomédica en Red en Salud Mental, CIBERSAM-Instituto de Salud Carlos III, 28029 Madrid, Spain.

Faith Matcham (F)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
School of Psychology, University of Sussex, East Sussex BN1 9QH, UK.

Femke Lamers (F)

Department of Psychiatry, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Amsterdam Public Health, Mental Health Program, 1081 BT Amsterdam, The Netherlands.

Matthew Hotopf (M)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Brenda W J H Penninx (BWJH)

Department of Psychiatry, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Amsterdam Public Health, Mental Health Program, 1081 BT Amsterdam, The Netherlands.

Peter Annas (P)

H. Lundbeck A/S, DK-2500 Valby, Denmark.

Vaibhav Narayan (V)

Research and Development Information Technology, Janssen Research & Development, LLC, Titusville, NJ 08560, USA.

Sara K Simblett (SK)

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.

Sara Siddi (S)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Departament de Medicina, Universitat de Barcelona, 08830 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH